Is the SS-31 peptide FDA-approved? No. Here's the current elamipretide status, trial results, research dosing, and safety concerns for US readers.
SS-31 (elamipretide) is not FDA-approved for any human use. As of 2025, the FDA has declined to approve elamipretide for Barth syndrome and for primary mitochondrial myopathy, and no prescription version of the peptide is legally available in the United States. That single fact shapes everything else on this page.
What Is SS-31 (Elamipretide)?
SS-31 is a synthetic tetrapeptide developed by Stealth BioTherapeutics and studied under the generic name elamipretide. It is designed to concentrate inside mitochondria, the energy-producing structures in your cells.
Unlike growth-hormone secretagogues or tissue-repair peptides, SS-31 is not marketed as a muscle or healing compound. Its proposed mechanism is mitochondrial: it binds to cardiolipin on the inner mitochondrial membrane and appears to stabilize electron transport while reducing oxidative stress.
- Class: mitochondria-targeted tetrapeptide
- Routes studied in humans: subcutaneous injection and intravenous infusion
- Developer: Stealth BioTherapeutics
- FDA status: not approved; investigational only
Any honest ss-31 peptide review has to start here: the compound has real human trial data, but it has never cleared the FDA's approval bar.
Is the SS-31 Peptide FDA-Approved? The Current Status
No. The FDA has repeatedly requested more evidence instead of granting approval. Rather than an approval letter, Stealth BioTherapeutics has received complete response letters, including for Barth syndrome and for primary mitochondrial myopathy (PMM).
An expanded access program has allowed some Barth syndrome patients to receive elamipretide outside of a trial. Expanded access is not approval, and it does not make the drug commercially available.
| Condition studied | Development stage | FDA status |
|---|---|---|
| Barth syndrome | Completed Phase 3; expanded access | Not approved (complete response letter) |
| Primary mitochondrial myopathy | Completed Phase 3 | Not approved |
| Dry age-related macular degeneration | Phase 2/3 (ReCLAIM program) | Not approved |
| Heart failure with reduced ejection fraction | Phase 2 (PROGRESS-HF) | Not approved |
Search results for ss-31 peptide fda approved are a mix of trial coverage and vendor marketing, and the vendor pages are the least reliable source of all. Any website claiming FDA approval for SS-31 should be treated as a red flag.
What Research Suggests About SS-31 Peptide Benefits
Published trials have explored whether elamipretide can improve exercise tolerance, cardiac function, and vision in specific disease populations. Results have been mixed, and several trials missed their primary endpoints.
- Barth syndrome: small trials reported improvements in some functional and cardiac measures, but the FDA found the evidence insufficient.
- Primary mitochondrial myopathy: the Phase 3 MMPOWER-3 trial did not meet its primary endpoint.
- Dry AMD: ReCLAIM-2 did not hit its primary endpoint, though some secondary signals were reported.
- Heart failure: early studies suggested possible hemodynamic effects, but larger trials have not confirmed a benefit.
A complete ss-31 peptide benefits and side effects picture therefore looks like this: plausible biology, promising early data, and disappointing late-stage results in most indications.
SS-31 Peptide Dosage Used in Clinical Research
The doses below come from published trial protocols and are listed for educational purposes only. They are not recommendations, and self-dosing with research-grade peptide carries serious risk.
| Trial population | Route | Reported dose |
|---|---|---|
| Barth syndrome | Subcutaneous | 40 mg once daily |
| Primary mitochondrial myopathy | Subcutaneous | 40 mg once daily |
| Dry AMD (ReCLAIM) | Subcutaneous | 40 mg once daily |
| Heart failure (early studies) | Intravenous infusion | Weight-based, infused over several hours |
Reported ss-31 peptide dosage schedules always sit inside a supervised protocol with monitoring, which is very different from the "one injection a day" advice found on forums.
SS-31 Peptide Side Effects and Safety Concerns
The most frequently reported adverse events in trials have been mild and injection-related.
- Injection site reactions such as pain, redness, or swelling
- Headache
- Nausea
- Dizziness or fatigue
Serious events have been uncommon in trials, but the total number of people exposed to elamipretide is small. Long-term safety in healthy adults has never been established, and unapproved products may contain impurities, incorrect concentrations, or no active peptide at all.
Because SS-31 is not FDA-approved, no dose, schedule, or duration can be described as safe or appropriate for human use outside a clinical trial. Talk with a licensed healthcare professional before considering any unapproved peptide.
SS-31 Peptide Bodybuilding and Gray-Market Sales
Elamipretide is not a muscle-building compound, and no human study has shown that it increases lean mass or strength. Claims about ss-31 peptide bodybuilding come from marketing, not from data.
Most SS-31 sold online is labeled "for research use only," which means it is not intended for human consumption and is not made under pharmaceutical standards. Because the peptide is unapproved, buyers have no guarantee of purity, sterility, or identity.
The Bottom Line
SS-31 (elamipretide) is investigational, not approved. The FDA has declined to approve it for Barth syndrome and primary mitochondrial myopathy, and there is no legal prescription version in the United States. Anyone who hears otherwise, especially from a seller, should verify the claim directly through the FDA's public drug databases.
Frequently Asked Questions
Is the SS-31 peptide FDA-approved for human use?
No. As of 2025, the FDA has not approved SS-31 (elamipretide) for any indication, including Barth syndrome and primary mitochondrial myopathy. The agency has issued complete response letters requesting additional evidence rather than granting approval.
Is SS-31 the same as elamipretide?
Yes. SS-31 is the research name for the peptide whose generic name is elamipretide, developed by Stealth BioTherapeutics. It has also appeared in the scientific literature under the code name MTP-131.
Can you legally buy SS-31 peptide in the United States?
You cannot buy an FDA-approved SS-31 product because none exists. Peptides sold online as SS-31 are typically labeled for research use only and are not legal to sell as dietary supplements or drugs for human consumption. Their purity, sterility, and actual content are unverified.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.